A guide to antibiotic resistance in bacterial skin infections

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 5, 2005, Pages 531-545

  Perera, G ^a   Hay, R ^b  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibiotics; Bacteria; Infection; MRSA; Resistance; Streptococcus

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BENZAMYCIN; CEPHALOSPORIN DERIVATIVE; CETRIMIDE; CHLORAMPHENICOL; CHLORHEXIDINE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DAPTOMYCIN; ERYTHROMYCIN; FLUCLOXACILLIN; FUSIDATE SODIUM; FUSIDIC ACID; HEXACHLOROPHENE; ISOTREXIN; LINEZOLID; METICILLIN; MINOCYCLINE; PENICILLIN G; POVIDONE IODINE; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; RIFAMPICIN; STER-ZAC; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN;

ACNE; ANEMIA; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL SKIN DISEASE; BONE MARROW SUPPRESSION; GRAM NEGATIVE INFECTION; HUMAN; LYME DISEASE; MYCOBACTERIUM TUBERCULOSIS; NECROTIZING FASCIITIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN FLORA; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GUIDELINES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, INFECTIOUS; TREATMENT OUTCOME;

EID: 28544443094     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01296.x     Document Type: Review

References (111)

1. Neu H. The crisis in antimicrobial resistance. Science 1992; 257: 1064-1073.
2. Kumin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118: 557-561.
3. Travis J. Reviving the antibiotic miracle? Science 1994; 264: 360-362.
4. Blumer JL, O'Brien CA, Lemon E, Capretta TM. Skin and soft tissue infections: pharmacologic approaches. Pediatric Infect Dis J 1985; 4: 336-341.
5. Blumer JL, Lemon E, O'Horo J, Snodgrass DJ. Changing therapy for skin and soft tissue infections in children: have we come full circle? Pediatric Infect Dis J 1987; 6: 117-122.
6. Roth PR, James WD. Microbiology of the skin: resident flora, ecology, and infection. J Am Acad Dermatol 1989; 20: 360-390.
7. Parish LC, Witkowski JA. Principles of anti-infective therapy. In: Marwali H, ed. Diagnosis and Treatment of Skin Infections. Blackwell Science, Oxford, 1997: 3.
8. Feingold DS. Bacterial adherence, colonisation and pathogenicity. Arch Dermatol 1986; 122: 161-163.
9. Wessels JC, Koelman HA, Steyn HS, Ellis SM. The application of new bioavailability parameters in the biosequence testing of antimicrobial agents. Int J Clin Pharmacol Ther Toxicol 1993; 11: 542-546.
10. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-381.
11. Sanders CC, Sanders WE Jr. Beta-lactam resistance in Gram-negative bacteria: global trends and clinical impact. Clin Infect Dis 1992; 15: 824-839.
12. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211-1233.
13. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264: 375-382.
14. Eda S, Maseda H, Nakae T. An elegant means of self-protection in Gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space. J Biol Chem 2003; 278: 2085-2088.
15. Mendez B, Tachibana C, Levy SB. Heterogeneity of tetracycline resistance determinants. Plasmid 1980; 3: 99-108.
16. Normak BH, Normak S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252: 91-106.
17. Dionisio F,Matic I, Radman M, Rodrigues OR, Taddei F. Plasmids spread very fast in heterogeneous bacterial communities. Genetics 2002; 162: 1525-1532.
18. Son R, Rusu G, Karim MI. Conjugal transfer of plasmids and antibiotic resistance among Escherichia coli isolated from animals in a rural area in Sarawak (Malaysia). J Appl Microbiol 1997; 82: 240-244.
19. Martinez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15: 647-679.
20. Scott KP. The role of conjugate transposons in spreading antibiotic resistance between bacteria that inhabit the gastrointestinal tract. Cell Mol Life Sci 2002; 59: 2071-2082.
21. Lindstedt BA, Heir E, Nygard I, Kapperud G. Characterisation of class I integrons in clinical strains of Salmonella enterica subsp. enterica serovars Typhimurium and Enteritidis from Norwegian hospitals. J Med Microbiol 2003; 52: 141-149.
22. Heuermann KG, Romero JR, Abromowitch MA, Gordon BG, Gross TG. Fatal coagulase-negative staphylococci infection after bone marrow transplant in a patient with persistent adverse reactions to vancomycin. J Pediatr Haematol Oncol 1999; 21: 80-81.
23. Jarlov J, Hojbjerg T, Busch-Sorensen C et al. Coagulase-negative staphylococci in Danish blood cultures: species distribution and antibiotic susceptibility. J Hosp Infect 1996; 32: 217-227.
24. Westh H, Hougaard DM, Vuust J, Rosdahl VT. Erm genes in erythromycin-resistant Staphylococcus aureus and coagulase-negative staphylococci. APMIS 1995; 103: 225-232.
25. Moreira BM, Daum RS. Antimicrobial resistance in staphylococci. Pediatr Clin North Am 1995; 42: 619-648.
26. Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999; 38: 265-269.
27. Akiyama H,Yamada T, Simoe K, Kanzaki H, Arat J. Characteristics and susceptibilities to antimicrobial agents of Staphylococcus aureus isolates isolated in dermatology. Chemotherapy (Japan) 1990; 38: 9-20.
28. Nishijima S, Namura S, Mitiuya K, Asada Y. The incidence of isolation of methicillin-resistant Staphylococcus aureus (MRSA) strains from skin infections during 1989-1991. J Dermatol 1993; 20: 192-197.
29. Skurray Ra Firth N. Molecular evolution of multiply antibiotic-resistant staphylococci. Ciba Found Symp 1997; 207: 167-183; discussion 183-191.
30. Trividic M, Gauthier ML, Sparsa A et al. Methi-resistant Staphylococcus aureus in dermatological practice: origin, risk factors and outcome. Ann Dermatol Venereol 2002; 129: 27-29.
31. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-139.
32. Adachi Y, Akamatsu H, Horio T. The effect of antibiotics on the production ot superantigen from Staphylococcus aureus isolated from atopic dermatitis. J Dermatol Sci 2002; 28: 76-83.
33. Wilkinson JD. Fusidc acid in dermatology. Br J Dermatol 1998; 139: 37-40.
34. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998; 139: 13-16.
35. Morley PA, Munot LD. A comparison of sodium fusidate ointment and mupirocin ointment in superficial skin sepsis. Curr Med Res Opin 1988; 11: 142-148.
36. Volker TA, Iida S, Bickle TA. A single gene encoding for resistance to both fusidic acid and chloramphenicol. J Mol Biol 1982; 154: 417-425.
37. Shah M, Mohanraj M. High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients. Br J Dermatol, 2003; 148: 1018-1020.
38. Brown EM, Thomas P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet 2002; 359: 803 [Letter].
39. Mason BW, Howard AJ, Magee JT. Fusidic acid resistance in community isolated of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing. J Antimicrob Chemother 2003; 51: 1033-1036.
40. R) Staphylococcus aureus in atopic eczema. Br J Dermatol 2003; 148: 1010-1017.
41. Kikuchi K, Takahashi N, Piao C et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus strains causing neonatal toxic shock syndrome-like exanthematous disease in neonatal and perinatal wards. J Clin Microbiol 2003; 41: 3001-3006.
42. Saunders NJ. Vancomycin administration and monitoring appraisal. J Antimicrob Chemother 1995; 36: 279-282.
43. French GL, Cheng AF, Ling JM, Mo P, Donnan S. Hong Kong strains ot methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990; 15: 117-125.
44. Chang S, Sievert DM, Hageman JC et al. Brief Report: Infection with vancomycin-resistant Staphylococcus aureus containing the van A-resistant gene. N Engl J Med 2003; 348: 1342-1347.
45. Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A, European VRE Study Group. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis 2000; 19: 816-822.
46. Howe RA, Monk A, Wootton M, Walsh TR, Enright MC. Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2004; 10: 855-857.
47. Linares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 2001; 7: 8-15.
48. Paulsen IT, Banerjei L, Myers GS et al. Role of mobile DNA in the resolution ot vancormcin-resistant Enterococcus faecalis. Science 2003; 299: 2071-2074.
49. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62: 425-441.
50. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
51. French G. Safety and tolerability of Linezolid. J Antimicrob Chemather 2003; 51: ii 45-53.
52. Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem 2003; 3: 1021-1042.
53. Fung HB, Kirschenbaum HL, Ojofeitimi BO. Linezolid: an oxazolidinone antimicrobial agent. Clin Ther 2001; 23: 356-391.
54. Johnson AP, Tysall L, Stockdale MV et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur Clin Microbiol Infect Dis 2002; 21: 751-754.
55. Nilius AM. Have the oxazolidinones lived up to their billing? Future perspective for this antibacterial class. Curr Opin Invest Drugs 2003; 4: 149-155.
56. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Invest Drugs 2004; 13: 1159-1169.
57. Martin MA. Methicillin-resistant Staphylococcus aureus: the persistent resistant nosocomial pathogen. Curr Clin Topics Infect Dis 1994; 14: 170-191.
58. Fernandez C, Gaspar C, Torrellas A et al. A double-blind randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995; 35: 399-408.
59. Cookson BD. Mupirocin resistance in staphylococci. J Antimicrob Chemother 1990; 25: 497-503.
60. Riley TV, Carson CF, Bowman RA et al Mupirocin-resistant methicillin-resistant Staphylococcus aureus in Western Australia. [Letter]. Med J Austral 1994; 161: 397-398.
61. Leigh DA, Joy G. Treatment of familial staphylococcal infection-comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemother 1993; 31: 909-917.
62. Darouiche R, Wright C, Hamil R et al. Eradication of colonisation by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampicin and topical mupirocin. Antimicrob Agents Chemother 1991; 35: 1612-1615.
63. Davies J, Babb JR, Ayliffe GA. The effect on the skin flora of bathing with antiseptic solutions. J Antimicrob Chemother, 1977; 3: 473-481.
64. Allen KD, Ridgway EJ, Parsons LA. Hexachlorophane powder and neonatal staphylococcal infection. J Hosp Infect 1994; 27: 29-33.
65. Watanakunakorn C, Axelson C, Bota B, Stahl C. Mupirocin ointment with and without chlorhexidine baths in the eradication of Staphylococcus aureus nasal carriage in nursing home residents. Am J Infect Control 1995; 23: 306-309.
66. Trividic M, Gauthier M-L, Sparsa A et al. Methi-resistant Staphylococcus aureus in dermatological practice: origin, risk factors and outcome. Ann Dermatol Vener 2002; 129: 27-29.
67. Papia G, Louie M, Tralla A et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999; 20: 473-477.
68. Girou E, Azar J, Wolkenstein P et al. Comparison of systematic versus selective screening for methicillin-resistant Staphylococcus aureus carriage in a high-risk dermatology ward. Infect Control Hosp Epidemiol 2000; 21: 583-587.
69. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999; 34: 65-72.
70. Solberg CO. Spread of Staphylococcus aureus in hospitals: causes and prevention. Scand J Infect Dis 2000; 32: 587-595.
71. Colsky AS, Kirsner RS, Kerdel FA. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol 1998; 134: 1006-1009.
72. Barrett SP, Mummery RV, Chattopadhyay B. Trying to control MRSA causes more problems than it solves. J Hosp Infect 1999; 39: 85-93.
73. Ameen H, Moore K, Lawrence JC, Harding KG. Investigating the bacterial barrier properties of four contemporary wound dressings. J Wound Care 2000; 9: 385-388.
74. Cox NH. Streptococcal necrotizing fasciitis and the dermatologist. Br J Dermatol 1999; 141: 613-614.
75. Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg 2000; 179: 361-366.
76. Holmstrom L, Nyman B, Rosengren M, Wallandr S, Ripa T. Outbreaks of infections with erythromycin-resistant group A Streptococcus pneumoniae in childcare centres. Scan J Infect Dis 1990; 22: 179-195.
77. Facinelli B, Spinaci C, Magi G, Giovanetti E, E Varaldo P. Association between erythromycin-resistance and ability to enter human respiratory tract cells in group A streptococci. Lancet 2001; 358: 30-31 [Comment].
78. Gerber MA. Antibiotic resistance in group A streptococci. Pediatric Clin North Am 1995; 42: 539-551.
79. Coonan KM, Kaplan EL. In vitro susceptibility of recent North American group A Streptococcal isolates to eleven oral antibiotics. Ped Infect Dis 1994; 13: 630-635.
80. Eagle H. Experimental approach to the problem of treatment failure with penicillin. 1. Group A Streptococcal infection in mice. Am J Med 1952; 13: 389-399.
81. Jones RN, Cormican MG, Wanger A. Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996; 24: 201-204.
82. Vardhan MS, Allen KD. Epidemiology of penicillin-resistant pneumococci in a Merseyside Health District over a 14-year period. J Infection 2003; 46: 23-29.
83. Canet JJ, Garau J. Importance of dose and duration of beta-lactam therapy in nasopharyngeal colonization with resistant pneumococci. J Antimicrob Chemo 2002; 50: 39-44.
84. Felmingham D, Reinert RR, Hirakata Y, Rodloff AA. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of ketolide, telithromycin. J Antimicrob Chemother 2002; 50: 25-37.
85. Kligman AM, Leyden JJ, McGinley KJ. Bacteriology. J Invest Dermatol 1976; 67: 160-168.
86. Kligman AM. An overview of acne. J Invest Dermatol 1974; 62: 268-287.
87. Marples RR, Leyden JJ, Stewart RN, Mills OH, Kligman AJ. The skin microflora in acne vulgaris. J Invest Dermatol 1974; 62: 37-41.
88. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Austral 1998; 169: 259-261.
89. Eady EA, Holland KT, Cunliffe WJ. The use of antibiotics in acne treatment: oral or topical administration. J Antimicrob Chemo 1982; 10: 89-115.
90. Miller YW, Eady EA, Lacey RW et al Sequential antibiotic therapy for acne promotes the carriage of resistant Staphylococci on the skin of contacts. J Antimicrob Chemother 1996; 38: 829-837.
91. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology 2003; 206: 54-56.
92. Bojar RA, Eady EA, Jones CE, Cunliffe WJ, Holland KT. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329-336.
93. Eady EA, Bojar RA, Jones CE et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br J Dermatol 1996; 134: 107-113.
94. Marazzi P, Boorrnan GC, Donald AE, Davies HD. Clinical evaluation of double-strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. J Dermatol Treatment 2002; 13: 111-117.
95. Gans EH, Kligman AM. Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibactenum acnes. J Dermatol Treatment 2002; 13: 107-110.
96. Eady EA, Jones CE, Gardner KJ et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol 1993; 128: 556-560.
97. Garner SE, Eady EA, Popescu C, Newton J, Li Wan Po A. Minocycline for acne vulgaris. [Systematic Review] Cochrane Skin Group. Cochrane Database of Systematic Reviews 2003; 1.
98. Eady EA, Coates P, Ross JL, Ratyal AH, Cove JH. Antibiotic resistance patterns of aerobic coryneforms and furazolidone-resistant Gram-positive cocci from the skin of the human axilla and fourth toe cleft. J Antimicrob Chemother 2000; 46: 205-213.
99. Agger WA, Mardan A. Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis 1995; 20: 302-308.
100. Garg P, Sharma S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmol 1999; 106: 1319-1323.
101. Reynolds R, Potz N, Colman M et al Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-02: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53: 1018-1032. Epub 2004 May 05.
102. ACP Journal Club. Single-dose doxycycline prevented Lyme disease after an Ixodes scapularis tick bite. ACP J Club 2002; 136: 56.
103. Terekhova D, Sartakova ML, Wormser GP, Schwartz I, Cabello FC. Erythromycin resistance in Borrelia burgdorferi. Antimicrob Agents Chemother 2002; 46: 3637-3640.
104. ACP Journal Club. Antimicrobial prophylaxis for Lyme disease. ACP J Club 1993; 118: 81.
105. Rao GG. Risk factors for the spread of antibiotic-resistant bacteria. Drugs 2002; 55: 323-330.
106. Barbagallo J, Tager P, Ingleton R, Hirsch RJ, Weinberg JM. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3: 319-328.
107. Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D. Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa. AIDS 1999; 13: 811-817.
108. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
109. British Thoracic Society. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
110. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998; 47: 7-10.
111. Nash K. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother 2001; 45: 1607-1614.